Cover Image

Differential Expression of Type 1 and Type 17 Immune Pathways and Chemokines in Mild‐to‐Severe Asthma With Mid to High Neutrophilic Inflammation

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Elisa Arrigo, Vitina Carriero, Francesca Bertolini, Stefano Levra, Camilla Demasi, Antonino Di Stefano, Daniela Miglietta, Gino Villetti, Fabio Luigi Massimo Ricciardolo
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Clinical & Experimental Allergy
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Genetically Determined Inflammation‐Related Proteins in Asthma and Type‐2 Signatures
by: Natalia Hernandez‐Pacheco, et al.
Published: (2025)

Type 2 Biomarkers as Mediators of Clinical Remission With Biologics in Severe Asthma
by: Duong Duc Pham, et al.
Published: (2025)

Role for Complement C5 in Eosinophilic Inflammation of Severe Asthma
by: Cong Dong, et al.
Published: (2025)

Real‐World Finetuning of Biomarkers in Severe Asthma: Longitudinal Latent Class Analysis From the Italian Registry on Severe Asthma ( IRSA )
by: M. Beatrice Bilò, et al.
Published: (2024)

Ficolin‐A Protects Against Allergic Asthma via Suppressing ILC2 ‐Drived Type 2 Inflammation
by: Yu‐ke Xie, et al.
Published: (2025)

High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma
by: Lorenz Wirth, et al.
Published: (2025)

How FEV 1 Improvement Induced by Anti‐ IL ‐5 in Severe Type‐2 Asthma Is Linked to Mucus Plugs Clearance
by: Alain Michils, et al.
Published: (2024)

Sensitisation to Staphylococcus Aureus Enterotoxin; a Driver of Airway Inflammation in Severe Asthma?
by: Freja Friis Lajer, et al.
Published: (2025)

Two Distinct Transcriptional Subtypes of Severe Type 2 Asthma in NSAID ‐Exacerbated Respiratory Disease
by: Radosław Kacorzyk, et al.
Published: (2026)

Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma
by: Michael E. Wechsler, et al.
Published: (2026)

Association Between Prevalence of Anemia and Asthma Severity
by: Mi‐So Kim, et al.
Published: (2025)

Reduced Type‐I Interferon by Plasmacytoid Dendritic Cells and Asthma in School‐Aged Children
by: Isabelle Coenen, et al.
Published: (2025)

An Algorithm for the Diagnosis and Management of Severe Asthma in Children and Adolescents
by: Eckard Hamelmann, et al.
Published: (2025)

Extracellular Vesicle miRNAs as Biomarkers of Asthma Severity
by: Chandrashekhar Prasad, et al.
Published: (2025)

Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes
by: Timothy C. Chin‐See‐Chong, et al.
Published: (2025)

Monocyte Chemotactic Factors in the Airways of Patients With Mild Asthma Before and After an Allergen Challenge
by: Nami Shrestha Palikhe, et al.
Published: (2025)

Distinct Phenotypes of Peripheral Innate Lymphoid Cells and T Cells in Type 2 and Non‐Type 2 Asthma
by: Maura M. Kere, et al.
Published: (2025)

Particulate Matter 2.5 Aggravates Airway Inflammation by Neutrophil‐Mediated Inflammasome Activation
by: Tien‐Hsuan Chen, et al.
Published: (2025)

Evidence of Eczematous Skin Characteristics in Mild Allergic Asthma
by: Anchalee Senavonge, et al.
Published: (2025)

Characteristics of Adolescents With Uncontrolled Severe Asthma Starting Dupilumab: The PEDIASTHMA Registry
by: Stéphanie Wanin, et al.
Published: (2025)

Dupilumab Effectiveness in Biologic‐Naïve and Switched Severe Asthma in Real Life
by: Catherine Moermans, et al.
Published: (2025)

Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab
by: Nuria Contreras, et al.
Published: (2024)

Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations
by: Mireille C. Melles, et al.
Published: (2026)

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab
by: Danilo Di Bona, et al.
Published: (2024)

Retrospective Analysis of Self‐Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
by: Hazal Kayıkçı, et al.
Published: (2025)

Oncostatin‐M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma
by: Stephane Esnault, et al.
Published: (2024)

Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma
by: Jessica Gates, et al.
Published: (2025)

Immune Training of the Interleukin 6 Gene in Airway Epithelial Cells is Central to Asthma Exacerbations
by: Lars P. Lunding, et al.
Published: (2025)

Reply to Correspondence “Omalizumab Reduces Anaphylactic Reactions and Allows Food Introduction in Food‐Allergic in Children With Severe Asthma: An Observational Study”
by: Stefania Arasi, et al.
Published: (2025)

Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma
by: Keita Hirai, et al.
Published: (2025)

Correspondence to “Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma”
by: C. Mümmler, et al.
Published: (2025)

Disruption of the Vagal TRPA1‐Pulmonary Neuroendocrine Cell Axis Reduces Asthma Severity
by: Xintong Feng, et al.
Published: (2025)

Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
by: Eve Denton, et al.
Published: (2024)

EAACI Guidelines on Environmental Science for Allergy and Asthma—Recommendations on the Impact of Indoor Air Pollutants on the Risk of New‐Onset Asthma and on Asthma‐Related Outcomes
by: Ioana Agache, et al.
Published: (2025)

Type 2 Inflammation‐Biased Arachidonic Acid Metabolite Regulates Mucosal Remodeling of Chronic Rhinosinusitis With Nasal Polyps
by: Ying Li, et al.
Published: (2026)

Correspondence to ‘Interleukin‐5 as a Pleiotropic Cytokine Orchestrating Airway Type 2 Inflammation: Effects on and Beyond Eosinophils’
by: Christopher McCrae, et al.
Published: (2025)

Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma
by: Marianne Baastrup Soendergaard, et al.
Published: (2024)

Correspondence: “Challenging the Frontier: Bridging Systemic Biomarkers and Small Airway Dynamics in Severe Asthma Management”
by: Ourania S. Kotsiou, et al.
Published: (2025)

Healthy Planet, Healthier People: EAACI's Integrated Planetary Health Strategy for Asthma, Allergies and Immune Diseases
by: André Moreira, et al.
Published: (2025)

Reply to Correspondence: ‘Challenging the Frontier: Bridging Systemic Biomarkers and Small Airway Dynamics in Severe Asthma Management’
by: Nuria Contreras, et al.
Published: (2025)